期刊
CANCER IMMUNOLOGY RESEARCH
卷 8, 期 6, 页码 769-780出版社
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2326-6066.CIR-19-0483
关键词
-
资金
- NIH (NCI) [R01 CA238039]
- Leukemia & Lymphoma Society
- Bristol-Myers Squibb
- Friends for Life Neuroblastoma Fellowship
- 2018 AACR-AstraZeneca Lung Cancer Research Fellowship [18-40-12-KUMA]
- Cancer Research Institute/Robertson Foundation Fellowship
- Cancer Immunology Training Grant [T32 CA207021]
Resistance to cytotoxic T cells is frequently mediated by loss of MHC class I expression or IFN gamma signaling in tumor cells, such as mutations of B2M or JAK1 genes. Natural killer (NK) cells could potentially target such resistant tumors, but suitable NK-cell-based strategies remain to be developed. We hypothesized that such tumors could be targeted by NK cells if sufficient activating signals were provided. Human tumors frequently express the MICA and MICB ligands of the activating NKG2D receptor, but proteolytic shedding of MICA/B represents an important immune evasion mechanism in many human cancers. We showed that B2M- and JAK1-deficient metastases were targeted by NK cells following treatment with a mAb that blocks MICA/B shedding. We also demonstrated that the FDA-approved HDAC inhibitor panobino-stat and a MICA/B antibody acted synergistically to enhance MICA/B surface expression on tumor cells. The HDAC inhibitor enhanced MICA/B gene expression, whereas the MICA/B antibody stabilized the synthesized protein on the cell surface. The combination of panobinostat and the MICA/B antibody reduced the number of pulmonary metastases formed by a human melanoma cell line in NOD/SCID gamma mice reconstituted with human NK cells. NK-cell-mediated immunity induced by a mAb specific for MICA/B, therefore, provides an opportunity to target tumors with mutations that render them resistant to cytotoxic T cells.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据